Blog tagged as Audit-Ready Imaging Data

As the market share leader across NCI Comprehensive Cancer Centers, Yunu has transformed imaging at scale through rapid adoption. What began as a trusted site solution is now a strategic platform for sponsors, bringing greater rigor, confidence, and consistency to central review workflows.

At DPHARM 2025, Patrick McNamara, Chief Commercial Officer at Yunu, shared how Yunu is redefining imaging in clinical research by solving site-level challenges first.

At DPHARM, Paul McCracken, Founder and Principal of RadiaNova Consulting, sheds light on the hidden challenges of clinical trial imaging and how radiopharmaceutical studies are transforming its role.

Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve Tolle, Chief Product & Technology Officer at Ignitedata, on how the updated ICH E6(R3) guidance is transforming imaging in clinical trials.

Site-level imaging errors affect up to 50% of oncology trial reads, delaying trials and potentially censoring patients. When quality is enforced at the point of capture, error rates drop by more than 80%, saving millions of dollars and months in trial timelines.

Moe Alsumidaie’s latest article explores how the updated ICH E6(R3) guidance raises the bar for imaging in clinical trials. With imaging as the primary endpoint in most oncology studies, sites and sponsors must now meet the same Good Clinical Practice (GCP) standards as other critical data types.